Table 1 In vitro combination of pracinostat (SB939) and pacritinib (SB1518)

From: The oral HDAC inhibitor pracinostat (SB939) is efficacious and synergistic with the JAK2 inhibitor pacritinib (SB1518) in preclinical models of AML

Cell line

Sequence

CI at ED 50 ±s.d.

CI at ED 90 ±s.d.

n

 

Simultaneously

0.89±0.1

0.77±0.1

 

MOLM-13 (FLT3 ITD)

SB939 first

1.49±0.3

1.48±0.4

2

 

SB1518 first

1.50±0.1

1.32±0.0

 
 

Simultaneously

0.55±0.1

0.41±0.2

 

MV4-11 (FLT3 ITD)

SB939 first

0.72±0.1

0.55±0.3

2

 

SB1518 first

1.69±0.5

2.49±1.3

 
 

Simultaneously

1.4±0.2

1.35±0.2

 

HL-60

SB939 first

1.35±0.5

1.57±0.3

4

 

SB1518 first

1.67±0.2

2.17±1.1

 
 

Simultaneously

1.6±0.2

1.7±0.1

 

KG1

SB939 first

1.3±0.5

1.0±0.2

2

 

SB1518 first

1.8±0.1

2.7±0.6

 
 

Simultaneously

0.91

1.27

 

SET-2 (JAK2mt)

SB939 first

1.13

0.95

1

 

SB1518 first

0.98

1.41

 
 

Simultaneously

2.07±0.9

2.40±1.4

 

HEL92.1.7 (JAK2 mt)

SB939 first

0.99±0.0

0.81±0.1

2

 

SB1518 first

2.12±1.0

2.30±0.7

 
 

Simultaneously

0.74±0.2

0.6±0.2

 

F36P (GM-CSFdep, JAK2 wt)

SB939 first

0.98±0.3

0.8±0.3

3

 

SB1518 first

1.81±0.8

1.9±1.0

 
  1. Abbreviations: CI, combinatorial indice; GM-CSF, granulocyte macrophage colony-stimulating factor; mt, mutant; wt, wild type.
Back to article page